Previous close | 0.0700 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.2400 |
Strike | 240.00 |
Expiry date | 2024-01-19 |
Day's range | 0.0700 - 0.0700 |
Contract range | N/A |
Volume | |
Open interest | 190 |
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).